{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '6.1.7', 'Pregnancy', 'Pregnancy in a study subject must be reported to AbbVie within 24 hours of the', 'investigative site becoming aware of the pregnancy. Subjects who become pregnant', 'during the study must be discontinued (Section 5.4).', 'All subjects should be informed that contraceptive measures (refer to Section 5.2.4,', 'Contraception Recommendations and Pregnancy Testing for the details on contraception)', 'should be taken throughout the study and for at least 6 months after the last dose of study', 'drug. Male subjects should be informed that contraceptive measures should be taken by', 'their female partner.', 'Information regarding a pregnancy occurrence in a study subject and the outcome of the', 'pregnancy will be collected. In the event of a pregnancy occurring in the partner of an', 'enrolled subject, written informed consent for release of medical information from the', 'partner must be obtained prior to the collection of any pregnancy-specific information,', 'and the pregnancy will be followed to outcome.', 'Pregnancy in a study subject is not considered an adverse event. The medical outcome for', 'either mother or infant, meeting any serious criteria including an elective or spontaneous', 'abortion is considered a serious adverse event and must be reported to Abb Vie within', '24 hours of the site becoming aware of the event.', '6.1.8', 'Toxicity Management', 'Subjects will be monitored continuously for toxicity while on study treatment. Toxicity', 'will be assessed using the National Cancer Institute Common Terminology Criteria for', 'Adverse Events (NCI CTCAE) Version 4.0.11 If a subject has an AE possibly related to', 'blinded investigational product administration, then dose interruptions/holds with possible', 'modifications as described below may be implemented. Adjustments to these guidelines', 'may occur based on the clinical judgment of the investigator with notification to the TA', 'MD. Dose modifications for toxicities as described in Section 5.5.4.2.2 are mandatory.', '84']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '6.1.8.1', 'Management of Serosal Effusions/Serositis', 'Serosal effusions (pleural or pericardial, or ascites) have been observed with', 'rovalpituzumab tesirine and have the potential to be life-threatening (e.g., cardiac', 'tamponade). Therefore, development of any of these events or worsening from baseline', 'warrants prompt evaluation by the Investigator or designee. Alternative causes such as', 'infection, congestive heart failure, or disease progression, should be ruled out. When', 'appropriate, a unifying diagnosis should be reported, e.g., \"heart failure,\" not the signs and', 'symptoms \"pleural effusion\" and \"edema limbs.\" Effusion events were reported during', 'treatment and may occur up to several months after last Rova-T dose. As a result,', 'subjects should be advised of signs and symptoms of fluid retention and contact treating', 'physician if they arise during this time.', 'When considered clinically significant (e.g., Grade 2 or higher and considered related to', 'blinded investigational product):', 'Systemic corticosteroids, when initiated promptly, have been reported to be', 'beneficial in some prior cases. The Investigator should consider a tapering', 'regimen, such as dexamethasone up to 8 mg orally twice a day for 5 days,', 'followed by 4 mg orally twice a day for 5 days, then 2 mg orally twice a day', 'for 5 days. Alternatively, nonsteroidal therapies for serositis may be', 'considered, such as non-steroidal anti-inflammatory drugs (NSAIDs,', 'e.g., ibuprofen 400 - 600 mg orally three to four times daily) or colchicine', '(e.g., 0.6 mg orally two to three times daily) given for 1 - 2 weeks.', 'Until clinical experience suggests otherwise, guidance for dose delay and/or', 'reduction, as well as criteria for ongoing dosing, should follow Section 5.5.4.2.', '6.1.8.2', 'Management of Skin Reactions', 'All cutaneous reactions which develop during treatment warrant prompt evaluation. Skin', 'toxicity with rovalpituzumab tesirine may consist of photosensitivity but possibly other', 'reactions such as palmar-plantar erythrodysesthesia or erythema multiforme. As such,', '85']\n\n###\n\n", "completion": "END"}